<DOC>
	<DOCNO>NCT01868893</DOCNO>
	<brief_summary>This multicenter , open-label , single-arm , expanded access treatment study design provide obinutuzumab patient previously untreated Chronic Lymphocytic Leukemia ( CLL ) combination chlorambucil evaluate safety efficacy obinutuzumab administer combination chlorambucil . This study enroll patient previously untreated CD20-positive CLL require treatment accord IWCLL guideline ( Hallek et al 2008 ) , assess investigator .</brief_summary>
	<brief_title>An Expanded Access , Open-Label Study Obinutuzumab ( GA101 ) Plus Chlorambucil Patients With Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Confirmed diagnosis CD20positive CLL ( per IWCLL guideline , Hallek et al 2008 ) Previously untreated CLL require treatment accord IWCLL guideline ( Hallek et al 2008 ) , assess investigator Adequate baseline bone marrow function unless due underlie CLL disease No previous treatment CLL chemotherapy , radiotherapy , immunotherapy Patients appropriate receive intensive chemotherapy judgment investigator Life expectancy &gt; 6 month Treatment investigational agent participation another clinical trial within 28 day prior start Cycle 1 Transformation CLL aggressive Bcell malignancy History severe allergic anaphylactic reaction monoclonal antibody therapy Known hypersensitivity chlorambucil excipients History malignancy could affect compliance protocol interpretation result Known active bacterial , viral , fungal , mycobacterial , infection ( exclude fungal infection nail bed ) major episode infection require treatment IV antibiotic hospitalization ( related completion course antibiotic ) within 4 week start Cycle 1 Major surgery ( within 4 week prior start Cycle 1 ) , diagnosis Known infection human immunodeficiency virus ( HIV ) Human TCell Leukemia Virus 1 ( HTLV1 ) seropositive status Positive hepatitis serology Women pregnant lactate Fertile men woman childbearing potential unless 1 ) surgically sterile 2 ) use adequate measure contraception oral contraceptive , intrauterine device , barrier method contraception conjunction spermicidal jelly Effective contraception require receive obinutuzumab . For woman , effective contraception require continue &gt; = 12 month last dose obinutuzumab . For men , effective contraception require continue 6 month last dose chlorambucil treatment . Vaccination live vaccine minimum 28 day prior start Cycle 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>